1例疑似美罗培南过敏安全使用亚胺培南西司他丁钠患者的药学监护

doi:10.19803/j.1672-8629.2021.09.20

中国药物警戒 ›› 2021, Vol. 18 ›› Issue (9): 887-889.
DOI: 10.19803/j.1672-8629.2021.09.20

1例疑似美罗培南过敏安全使用亚胺培南西司他丁钠患者的药学监护

马雪¹, 漆婷婷², 余文韬^1,*

¹四川省肿瘤医院研究所,四川省癌症防治中心,四川成都610041;
²电子科技大学医学院药学部,四川成都610041

收稿日期:2020-01-13 出版日期:2021-09-15 发布日期:2021-09-18
通讯作者: ^*余文韬,男,硕士,主管药师,临床药学。E-mail：summeyu211@outlook.com
作者简介:马雪,女,硕士,主管药师,临床药学。
基金资助:
四川省重点研发计划（2018SZ0268）

Pharmaceutical Care of a Patient Suspected to Be Allergic to Meropenem and Treated with Imipenem/Cisstatine Sodium

MA Xue¹, QI Tingting², YU Wentao^1,*

¹Department of Pharmacy, School of Medicine, University of Electronic Science and Technology, Sichuan Cancer Center, Chengdu Sichuan 610041, China;
²Cancer Hospital & Institute, Chengdu Sichuan 610041, China

Received:2020-01-13 Online:2021-09-15 Published:2021-09-18

摘要/Abstract

摘要： 目的探讨使用一种碳青霉烯类药物发生过敏时患者的药学监护,以及不同β-内酰胺类、不同碳青霉烯类药物之间交叉过敏反应的发生情况与发生机制。方法对1例结肠癌术后继发严重腹腔感染的老年男性患者使用美罗培南后出现全身散在皮疹的用药情况进行分析,并积极抗过敏,换用亚胺培南西司他丁钠继续抗感染治疗,给予全程药学监护。结果患者经过积极治疗,皮疹消退,未再出现其他过敏反应,治疗20 d后好转出院。结论碳青霉烯类药物发生过敏主要与其各自的侧链有关,如无法避免使用,在已知一种碳青霉烯类过敏的情况下,建议谨慎选择另一种碳青霉烯药物。

关键词: 美罗培南, 亚胺培南西司他丁钠, 过敏

Abstract: Objective To investigate the pharmaceutical care of one patient allergic to carbapenems and analyze the occurrence and mechanism of cross-reactivity betweenβ-lactams and carbapenems. Methods The medication of an elderly male patient who had been treated with meropenem following severe abdominal infection after colon cancer surgery and developed skin rash was analyzed. The patient was then treated with imipenem acetaminophen sodium in conjunction with anti-allergy drugs and pharmaceutical care. Results After twenty days of anti-infection treatment, the patient’s rash subsided and there were no other allergic reactions before he was discharged after improvement. Conclusion Limited studies have shown that the occurrence of allergies is mainly related to the side chain. If carbapenem has to be used, cautious administration of an alternative carbapenem should be considered for patients with previous allergy to another carbapenem.

Key words: meropenem, imipenem/cisstatine, allergy

中图分类号:

R969.3

马雪, 漆婷婷, 余文韬. 1例疑似美罗培南过敏安全使用亚胺培南西司他丁钠患者的药学监护[J]. 中国药物警戒, 2021, 18(9): 887-889.

MA Xue, QI Tingting, YU Wentao. Pharmaceutical Care of a Patient Suspected to Be Allergic to Meropenem and Treated with Imipenem/Cisstatine Sodium[J]. Chinese Journal of Pharmacovigilance, 2021, 18(9): 887-889.

参考文献

[1] Bauer SL, Wall GC, Skoglund KJ, et al.Lack of cross-reactivity to meropenem in a patient with an allergy to imipenem-cilastatin[J]. J Allergy Clin Immunol, 2004(113): 173-175.
[2] Romano A, Gaeta F, Poves MFA, et al.Cross-Reactivity among Beta-Lactams[J]. Current Allergy and Asthma Reports, 2016, 16(3): 24.
[3] Yang H, Wei J, Wang JY, et al.Study on evaluation methods of adverse drug reaction/event report[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2009, 6(10): 581-584.
[4] Naranjo CA, Busto U, Sellers EM, et al.A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther, 1981, 30(2): 239-245.
[5] Kula B, Djordjevic G, Robinson JL.A systematic review: can one prescribe carbapenems to patients with ige-mediated allergy to penicillins or cephalosporins?[J]. Clinical Infectious Diseases, 2014, 59(8): 1113-1122.
[6] Picard M, Robitaille G, Karam F, et al.Cross-reactivity to cephalosporins and carbapenems in penicillin-allergic patients: two systematic reviews and meta-analyses[J]. J Allergy Clin Immunol Pract, 2019, 7(8): 2722-2738.
[7] Romano A, Gaeta F, Valluzzi RL, et al.IgE-mediated hyperse-nsitivity to cephalosporins: Cross-reactivity and tolerability of penicillins, monobactams, and carbapenems[J]. J Allergy Clin Immunol, 2010, 126(5): 994-999.
[8] Lakhal K, Lortat-Jacob B, Neukirch C, et al.Safe use of meropenem in a patient with a possible nonimmediate allergy to imipenem[J]. Pharmacotherapy, 2007, 27(9): 1334-1338.
[9] Lee Y, Bradley N.Overview and insights into carbapenem allergy[J].Pharmacy (Basel), 2019, 7(3): 110.
[10] Robinson JL, Hameed T, Carr S.Practical aspects of choosing an antibiotic for patients with a reported allergy to an antibiotic[J]. Clinical Infectious Diseases, 2002, 35(1): 26-31.
[11] Noguerado-Mellado B, Pinto Fernández C, Pineda-Pineda R, et al.Cross-reactivity between carbapenems: two case reports[J]. The Journal of Allergy and Clinical Immunology: In Practice, 2014, 2(6): 816-817.
[12] Gil-Serrano J, Cardona V, Luengo O, et al.Anaphylactic shock to meropenem with ertapenem tolerance: a case report[J]. J Allergy Clin Immunol Pract, 2019, 7(6): 2057-2058.
[13] Expert committee on clinical use of antimicrobials and evaluation of antimicrobal resistance. Penicillin skin test expert consensus[J]. Natl Med J China(中华医学杂志), 2017, 97(40): 3143-3146.
[14] Zhejiang Pharmaceutical Administration Quality Control Center, Zhejiang Society of Microbiology and Immunology, Zhejiang Nursing Quality Control Center. Guidance on skin allergy test of cephalosporin antibiotics in Zhejiang province[S]. 2018. . Guidance on skin allergy test of cephalosporin antibiotics in Zhejiang province[S]. 2018. http://t5.1il.cn/TZGG/ShowContent_11454.html.
[15] Chongqing Pharmaceutical Administration Quality Control Center. Consensus on skin allergy test of cephalosporin antibacterial agents in Chongqing[S]. 2018[2020-01-01]. . Consensus on skin allergy test of cephalosporin antibacterial agents in Chongqing[S]. 2018[2020-01-01]. http://www.clinphar.cn/thread-417911-1-1.html.
[16] Morgado F, Santiago L, Gonçalo M.Safe use of imipenem after delayed hypersensitivity to meropenem-Value of patch tests[J]. Contact Dermatitis, 2020, 82(3): 190-191.

1例疑似美罗培南过敏安全使用亚胺培南西司他丁钠患者的药学监护

Pharmaceutical Care of a Patient Suspected to Be Allergic to Meropenem and Treated with Imipenem/Cisstatine Sodium

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[2]	李娜, 郭军, 郭文佳, 吕茵茵, 李彩宏, 牟向东. 奥马珠单抗注射剂治疗哮喘致迟发型皮肤过敏反应1 例分析[J]. 中国药物警戒, 2024, 21(2): 211-212.
[3]	臧天颖, 刘炳阳, 唐晓军. 万古霉素所致类过敏与过敏反应的鉴别研究进展[J]. 中国药物警戒, 2023, 20(9): 1078-1080.
[4]	王然, 李轶凡, 刘小艳, 冯欣. 1例妊娠期药物暴露风险的药学监护[J]. 中国药物警戒, 2023, 20(8): 933-934.
[5]	孟康康, 刘赛月. 辅酶Q10注射剂上市后安全性分析[J]. 中国药物警戒, 2023, 20(7): 795-798.
[6]	刘婧, 夏亮, 张世杰. 1例多元药物过敏急性胰腺炎患者行药物激发试验的药学监护[J]. 中国药物警戒, 2023, 20(7): 822-824.
[7]	连玉菲, 邱学佳, 方灵芝, 张玥, 刘洪涛, 董占军. 氟替美维吸入粉雾剂致过敏性休克1例分析[J]. 中国药物警戒, 2023, 20(7): 829-832.
[8]	陈诚, 邓莉, 刘松青, 杜倩, 奚鑫. 重庆市2015年至2020年药源性过敏性休克报告分析[J]. 中国药物警戒, 2023, 20(4): 460-464.
[9]	刘保华, 沈爱宗, 苏丹. 1例注射用美罗培南联合注射用万古霉素致严重骨髓抑制的药学监护[J]. 中国药物警戒, 2023, 20(3): 339-342.
[10]	柯兵兵, 李燕, 王平慧, 徐晓玲, 沈佳特, 吕晓君. 基于小鼠耳廓蓝染实验评价静注人免疫球蛋白（pH4.0）类过敏反应[J]. 中国药物警戒, 2023, 20(12): 1357-1361.
[11]	张静宇, 张媛媛, 王晶, 马博, 李文娟. 炎琥宁注射剂致儿童严重过敏反应的影响因素分析[J]. 中国药物警戒, 2022, 19(9): 1019-1022.
[12]	姚羽, 黎元元, 魏戌, 谢雁鸣, 王志飞, 高明慧. 真实世界中鹿瓜多肽注射液疑似过敏反应影响因素研究[J]. 中国药物警戒, 2022, 19(7): 740-743.
[13]	杨莲娣. 利塞膦酸钠片致过敏性休克1例分析[J]. 中国药物警戒, 2022, 19(7): 795-798.
[14]	易艳, 田婧卓, 李春英, 赵雍, 梁爱华. 中药注射剂上市后非临床安全性再评价类过敏反应相关研究[J]. 中国药物警戒, 2022, 19(2): 185-188.
[15]	滕威, 逄晓云. 某三甲医院2009年至2019年药物相关过敏性休克报告分析与救治[J]. 中国药物警戒, 2022, 19(2): 196-199.